Vascular endothelial growth factor biology: clinical implications for ocular treatments
- 17 August 2006
- journal article
- review article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 90 (12) , 1542-1547
- https://doi.org/10.1136/bjo.2006.098426
Abstract
Decades of research on vascular endothelial growth factor (VEGF) have reached fruition with the recent development of intravitreal anti-VEGF treatments for exudative age-related macular degeneration. VEGF is a critical regulator of angiogenesis and vascular permeability with diverse roles, both pathological and physiological, during development and adulthood. The aim of this article is to review aspects of VEGF biology that may be relevant to the clinical use of anti-VEGF agents in ophthalmology: molecular characteristics and isoforms of VEGF; its roles in vasculogenesis, vascular maintenance and angiogenesis; systemic effects of VEGF inhibition; and properties of current anti-VEGF agents.Keywords
This publication has 72 references indexed in Scilit:
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Sequential Steps During Vasculogenesis and Angiogenesis in the Very Early Human PlacentaPlacenta, 2006
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signalingAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF 165Proceedings of the National Academy of Sciences, 2005
- A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular EdemaPublished by Elsevier ,2005
- Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusionAlbrecht von Graefes Archiv für Ophthalmologie, 2005
- Placenta Growth Factor and Vascular Endothelial Growth Factor B and C Expression in Microvascular Endothelial Cells and PericytesJournal of Biological Chemistry, 1999